Literature DB >> 11280930

Vaccine trials.

C P Farrington1, E Miller.   

Abstract

This article reviews some of the issues involved in evaluating vaccines in humans. Vaccine trials are required for licensure and are essential for demonstrating a vaccine's safety and protective efficacy. The formal framework of phase I, II, and III trials is described, with particular emphasis on the choice of hypotheses, trial design, and biases that arise in the context of vaccine trials. However, some aspects of a vaccine's performance cannot be evaluated in clinical trials owing to their relatively small size. Thus, vaccine evaluation must continue after licensure, for example, to evaluate the vaccine with respect to rare reactions, duration of protection, and ecological effects. The article reviews some of the methods commonly used for post-licensure studies of vaccine efficacy and safety.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280930     DOI: 10.1385/MB:17:1:43

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  63 in total

1.  World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

2.  Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine.

Authors:  C H Simanjuntak; F P Paleologo; N H Punjabi; R Darmowigoto; H Totosudirjo; P Haryanto; E Suprijanto; N D Witham; S L Hoffman
Journal:  Lancet       Date:  1991-10-26       Impact factor: 79.321

3.  Randomization by group: a formal analysis.

Authors:  J Cornfield
Journal:  Am J Epidemiol       Date:  1978-08       Impact factor: 4.897

4.  Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month-old children, including comparison of arm versus thigh injection.

Authors:  D Scheifele; G Bjornson; L Barreto; W Meekison; R Guasparini
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

5.  A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.

Authors:  P Farrington; S Pugh; A Colville; A Flower; J Nash; P Morgan-Capner; M Rush; E Miller
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

6.  Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (ts) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate.

Authors:  J A Bellanti; B J Zeligs; S Vetro; Y H Pung; S Luccioli; M J Malavasic; A M Hooke; T R Ubertini; R Vanni; L Nencioni
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

7.  Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador.

Authors:  F Sempértegui; B Estrella; J Moscoso; L Piedrahita; D Hernández; J Gaybor; P Naranjo; O Mancero; S Arias; R Bernal
Journal:  Vaccine       Date:  1994-03       Impact factor: 3.641

8.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

9.  Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba.

Authors:  G V Sierra; H C Campa; N M Varcacel; I L Garcia; P L Izquierdo; P F Sotolongo; G V Casanueva; C O Rico; C R Rodriguez; M H Terry
Journal:  NIPH Ann       Date:  1991-12

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Artificial Intelligence-Based Data-Driven Strategy to Accelerate Research, Development, and Clinical Trials of COVID Vaccine.

Authors:  Ashwani Sharma; Tarun Virmani; Vipluv Pathak; Anjali Sharma; Kamla Pathak; Girish Kumar; Devender Pathak
Journal:  Biomed Res Int       Date:  2022-07-06       Impact factor: 3.246

Review 2.  Emerging vaccine informatics.

Authors:  Yongqun He; Rino Rappuoli; Anne S De Groot; Robert T Chen
Journal:  J Biomed Biotechnol       Date:  2011-06-15

Review 3.  The clinical development process for a novel preventive vaccine: An overview.

Authors:  K Singh; S Mehta
Journal:  J Postgrad Med       Date:  2016 Jan-Mar       Impact factor: 1.476

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.